Status:
UNKNOWN
Effect of Gene Polymorphisms on the Pathogenesis of Cancer Cachexia
Lead Sponsor:
Cairo University
Collaborating Sponsors:
Misr International University
Ain Shams University
Conditions:
Cancer Cachexia
Eligibility:
All Genders
18-80 years
Brief Summary
Cachexia not only directly increases the morbidity and mortality, it also aggravates the side effects of chemotherapy and reduces the overall quality of life that is often considered the major and dir...
Detailed Description
Cachexia is a devastating syndrome that is observed in the majority of end stage cancer patients. Primary symptoms of cancer cachexia comprise of progressive loss in weight and exhaustion of host skel...
Eligibility Criteria
Inclusion
- Patients with medical diagnosis of cancer (eg, lung, pancreas, gastric, biliary, small intestine, or colorectal) Locally, advanced or metastatic cancer scheduled for the first line cytotoxic chemotherapy were eligible for inclusion. Patients who were starting or continuing chemotherapy at the time of screening for participants
- The duration was set based on standard period of first line chemotherapy
- Age of 18 years to 80 years
- Written informed consent of the subject to participate in the study
Exclusion
- Planned to have surgical procedures at the time of recruitment
- Underwent surgery during the study or in the month prior to the study and did not have chemotherapy scheduled postsurgery
- Had any comorbidities that could affect the interpretation of study findings (eg, HIV, AIDS, Alzheimer's disease, movement disorder, acute myocardial infarction within last 3 months, hepatitis)
- Had open burn sites or infected wounds
- Were diagnosed with esophageal cancer with a swallowing difficulty in mechanical nature
- Had an uncorrected, mechanical digestive obstruction
- Pregnant or nursing women
- Disorders associated with change in micro RNA (miR-155) level (Rheumatic Arthritis, Osteoarthritis, Atopic Eczema, Down Syndrome, Breast cancer, Endometrioid adenocarcinoma, AML, CLL, PC thyroid tumors)
- Inflammatory and autoimmune diseases (Multiple Sclerosis, Psoriasis and Systemic Lupus Erythematous)
Key Trial Info
Start Date :
June 20 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04131478
Start Date
June 20 2019
End Date
January 1 2021
Last Update
November 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Egypt, 11314